Multiple Myeloma Clinical Trial

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma


The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.

View Full Description

Full Description

This is a randomized (participants will be assigned by chance to study treatments), open-label (all participants and study personnel will know the identity of the study treatments), active-controlled (none of the study treatments are placebo), parallel-group (both treatment arms will run at the same time), multicenter study. In this study, daratumumab, lenalidomide, and low-dose dexamethasone (DRd) will be compared with lenalidomide and low dose dexamethasone (Rd) in participants with relapsed or refractory multiple myeloma. Participants will be randomized in a 1:1 ratio to receive either DRd or Rd. The study will include a Screening Phase, a Treatment Phase (involving treatment cycles of approximately 28 days in length), and a Follow-up Phase. The Treatment Phase will extend from the administration of the first dose of study medication until disease progression or unacceptable toxicity. Participants will also discontinue study treatment if: they become pregnant; have their dose held for more than 28 days (or if 3 consecutive planned doses of daratumumab are missed for reasons other than toxicity); or for safety reasons (for example, adverse event). The Follow-up Phase will begin at the end of treatment and will continue until death, loss to follow-up, consent withdrawal for study participation, or the final overall survival (OS) analysis, whichever occurs first. Eligible participants from Rd group who have had sponsor confirmed disease progression will be offered the option for treatment with daratumumab monotherapy (of 28 days cycle). The primary endpoint will be progression-free survival (PFS). Analysis of the primary endpoint was performed at a pre-specified point determined by PFS events with a clinical cutoff of March 7, 2016 when 169 events of death or progression had occurred. The end of study is anticipated at approximately 6 years after the last participant is randomized. Blood and urine samples will be obtained at time points during the study, together with bone marrow aspirates/biopsies and skeletal surveys. Participant safety will be assessed throughout the study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Must have documented multiple myeloma and measurable disease
Must have received at least 1 prior line of therapy for multiple myeloma and achieved a response (partial response or better) to at least one prior regimen
Must have documented evidence of progressive disease as defined by the International Myeloma Working Group criteria on or after their last regimen
Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2
If a participant has received subsequent anticancer therapy (salvage therapy), the participant must have a "wash-out period" defined as 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the planned start date of daratumumab monotherapy. The only exception is the emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day for a maximum of 4 days) before Daratumumab monotherapy

Exclusion Criteria:

Has received any of the following therapies: daratumumab or other anti-CD38 therapies
Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment
Disease shows evidence of refractoriness or intolerance to lenalidomide or if previously treated with a lenalidomide-containing regimen the participant is excluded if he or she discontinued due to any adverse event related to prior lenalidomide treatment
Has received autologous stem cell transplantation within 12 weeks before the date of randomization, or previously received an allogenic stem cell transplant (regardless of timing), or planning to undergo a stem cell transplant prior to progression of disease
History of malignancy (other than multiple myeloma) within 5 years before the first dose of daratumumab monotherapy (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 5 years)

Study is for people with:

Multiple Myeloma


Phase 3

Estimated Enrollment:


Study ID:


Recruitment Status:

Active, not recruiting


Janssen Research & Development, LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?


There is 1 Location for this study

See Locations Near You

Little Rock Arkansas, , United States

Gainesville Florida, , United States

West Palm Beach Florida, , United States

Atlanta Georgia, , United States

Chicago Illinois, , United States

Iowa City Iowa, , United States

Louisville Kentucky, , United States

Baton Rouge Louisiana, , United States

New Orleans Louisiana, , United States

Bethesda Maryland, , United States

Columbia Maryland, , United States

Boston Massachusetts, , United States

Rochester Minnesota, , United States

Omaha Nebraska, , United States

New Brunswick New Jersey, , United States

New York New York, , United States

Charlotte North Carolina, , United States

Eugene Oregon, , United States

Spartanburg South Carolina, , United States

Austin Texas, , United States

Dallas Texas, , United States

Houston Texas, , United States

Fairfax Virginia, , United States

Camperdown , , Australia

Geelong , , Australia

Heidelberg , , Australia

Malvern , , Australia

South Brisbane , , Australia

Southport , , Australia

Anderlecht , , Belgium

Antwerpen , , Belgium

Edegem , , Belgium

Gent , , Belgium

Kortrijk , , Belgium

Leuven , , Belgium

Liege , , Belgium

Calgary Alberta, , Canada

Edmonton Alberta, , Canada

Surrey British Columbia, , Canada

Vancouver British Columbia, , Canada

Halifax Nova Scotia, , Canada

Hamilton Ontario, , Canada

London Ontario, , Canada

Toronto Ontario, , Canada

Montreal Quebec, , Canada

Quebec City Quebec, , Canada

Copenhagen , , Denmark

Odense , , Denmark

Vejle , , Denmark

Argenteuil , , France

Caen , , France

Lille , , France

Limoges , , France

Nantes Cedex 1 , , France

Paris , , France

Pessac , , France

Pierre Benite , , France

Rennes , , France

Toulouse Cedex 9 , , France

Tours Cedex 9 , , France

Vandoeuvre les Nancy , , France

Berlin , , Germany

Bonn , , Germany

Hamburg , , Germany

Hamm , , Germany

Heidelberg , , Germany

Jena , , Germany

Karlsruhe , , Germany

Koblenz , , Germany

Köln , , Germany

Saarbrücken , , Germany

Villingen-Schwenningen , , Germany

Athens Attica , , Greece

Haifa , , Israel

Jerusalem , , Israel

Nahariya , , Israel

Netanya , , Israel

Petah Tikva , , Israel

Ramat Gan , , Israel

Tel Aviv , , Israel

Hitachi , , Japan

Kanazawa , , Japan

Kobe , , Japan

Kurume , , Japan

Matsuyama , , Japan

Nagoya , , Japan

Narita , , Japan

Ohgaki , , Japan

Okayama , , Japan

Osaka , , Japan

Sendai-City , , Japan

Shibukawa , , Japan

Shibuya , , Japan

Tachikawa , , Japan

Tokyo , , Japan

Gyeonggi-do , , Korea, Republic of

Incheon , , Korea, Republic of

Seoul , , Korea, Republic of

Amsterdam , , Netherlands

Rotterdam , , Netherlands

Utrecht , , Netherlands

Zwolle , , Netherlands

Brzozow , , Poland

Chorzów , , Poland

Gdansk , , Poland

Legnica , , Poland

Lublin , , Poland

Poznan , , Poland

Slupsk , , Poland

Wroclawa , , Poland

Dzerzhinsk , , Russian Federation

Ekaterinburg , , Russian Federation

Moscow , , Russian Federation

Nizhny Novgorod , , Russian Federation

Petrozavodsk , , Russian Federation

Ryazan , , Russian Federation

Samara , , Russian Federation

St-Petersburg , , Russian Federation

St. Petersburg , , Russian Federation

Syktyvkar , , Russian Federation

Badalona , , Spain

Barcelona , , Spain

La Laguna (Santa Cruz De Tenerife) , , Spain

Madrid , , Spain

Pamplona , , Spain

Salamanca , , Spain

Sevilla , , Spain

Falun , , Sweden

Göteborg , , Sweden

Helsingborg , , Sweden

Huddinge , , Sweden

Lund , , Sweden

Stockholm , , Sweden

Uppsala , , Sweden

Changhua , , Taiwan

Taichung City , , Taiwan

Tainan , , Taiwan

Taipei , , Taiwan

Taoyuan , , Taiwan

Birmingham , , United Kingdom

Leeds , , United Kingdom

London , , United Kingdom

Oxford , , United Kingdom

Southampton , , United Kingdom

Surrey , , United Kingdom

Wolverhampton , , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma


Phase 3

Estimated Enrollment:


Study ID:


Recruitment Status:

Active, not recruiting


Janssen Research & Development, LLC

How clear is this clinincal trial information?


Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.